CAT II used to be the empiric treatment regimen for treatment failures, defaulters and TB relapse.
It was recently observed in multiple observational studies that the outcomes among individuals receiving category II treatment had mixed results. The overall success rates are 60–80% with notably worse outcomes among patients with treatment failures. The incidence of Drug Resistance amongst such patients is very high (INH mono/poly resistance, Multi-Drug Resistance). Patients with relapse or defaulters had a better outcome. Hence there was a serious concern on continued use of empiric regimens. The MoHFW has hence withdrawn CAT II ATT regimen from immediate effect.
Read more related information, Click Here
If you have a question on some other topic, Click Here